Longeveron Inc. (LGVN)
Automate Your Wheel Strategy on LGVN
With Tiblio's Option Bot, you can configure your own wheel strategy including LGVN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LGVN
- Rev/Share 0.1488
- Book/Share 1.3298
- PB 1.0543
- Debt/Equity 0.0368
- CurrentRatio 5.6076
- ROIC -0.939
- MktCap 18161259.0
- FreeCF/Share -1.0404
- PFCF -1.1676
- PE -1.0689
- Debt/Assets 0.0303
- DivYield 0
- ROE -0.8506
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LGVN | ROTH MKM | -- | Buy | -- | $10 | Dec. 6, 2024 |
News
Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Published: June 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa'el Hashad, CEO, will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025.
Read More
Longeveron® to Attend BIO International Convention 2025
Published: May 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Longeveron to host Alzheimer's disease program partnering meetings at BIO 2025 conference June 16-19. Positive Phase 2a data published in Nature Medicine.
Read More
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapy Stem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer's disease and HLHS, a rare pediatric disease and orphan-designated indication MIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition. “We're proud to be a Semifinalist team …
Read More
Longeveron® to Present at the 37th Annual Roth Conference
Published: March 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, March 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the 37th Annual Roth Conference taking place March 17-18, 2025. Details for the Company's fireside chat: Date: Tuesday, March 18, 2025 Time: 9:00 – 9:25 a.m.
Read More
About Longeveron Inc. (LGVN)
- IPO Date 2021-02-12
- Website https://www.longeveron.com
- Industry Biotechnology
- CEO Mr. Mohamed Wa'el Ahmed Hashad M.B.A.
- Employees 25